Home  »  Companies   »  Which Institutions Own Shares In Hancock Jaffe Lab...

Which Institutions Own Shares In Hancock Jaffe Laboratories Inc. (HJLI)?

12 institutions hold shares in Hancock Jaffe Laboratories Inc. (HJLI), with 31.21k shares held by insiders accounting for 1.23% while institutional investors hold 7.13% of the company’s shares. The shares outstanding are 8.50M, and float is at 2.18M with Short Float at 17.88%. Institutions hold 7.04% of the Float.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

The top institutional shareholder in the company is Virtu Financial LLC with over 26107.0 shares valued at $0.23 million. The investor’s holdings represent 1.01% of the HJLI Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 17570.0 shares valued at $0.15 million to account for 0.68% of the shares outstanding. The other top investors are UBS Group AG which holds 1196.0 shares representing 0.05% and valued at over $10345.0, while Advisor Group, Inc. holds 0.02% of the shares totaling 600.0 with a market value of $5190.0.

Hancock Jaffe Laboratories Inc. (NASDAQ: HJLI) is -17.34% lower on its value in year-to-date trading and has touched a low of $5.55 and a high of $20.25 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The HJLI stock was last observed hovering at around $6.81 in the last trading session, with the day’s gains setting it 0.34% off its average median price target of $28.00 for the next 12 months. It is also 74.46% off the consensus price target high of $28.00 offered by 1 analysts, but current levels are 74.46% higher than the price target low of $28.00 for the same period.

Currently trading at $7.15, the stock is 5.23% and -7.28% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.51 million and changing 4.99% at the moment leaves the stock -19.97% off its SMA200. HJLI registered 0.35% gain for a year compared to 6-month loss of -34.84%. The firm has a 50-day simple moving average (SMA 50) of $7.11 and a 200-day simple moving average (SMA200) of $8.55.

The stock witnessed a 15.51% gain in the last 1 month and extending the period to 3 months gives it a -17.34%, and is 8.66% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.04% over the week and 8.09% over the month.

Distance from 52-week low is 28.83% and -64.69% from its 52-week high.

Hancock Jaffe Laboratories Inc. (HJLI) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Hancock Jaffe Laboratories Inc. (HJLI) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 1.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Hancock Jaffe Laboratories Inc. is expected to release its quarterly report on 09/01/2021 and quarterly earnings per share for the current quarter are estimated at -$0.19.The EPS is expected to grow by 72.30% this year

Hancock Jaffe Laboratories Inc. (HJLI) Insider Activity

A total of 0 insider transactions have happened at Hancock Jaffe Laboratories Inc. (HJLI) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Biodyne Holding, S.A., the company’s Former 10% Owner. SEC filings show that Biodyne Holding, S.A. sold 75,000 shares of the company’s common stock on Aug 21 at a price of $0.38 per share for a total of $28500.0. Following the sale, the insider now owns 1.41 million shares.

Hancock Jaffe Laboratories Inc. disclosed in a document filed with the SEC on Aug 20 that Biodyne Holding, S.A. (Former 10% Owner) sold a total of 75,000 shares of the company’s common stock. The trade occurred on Aug 20 and was made at $0.27 per share for $20250.0. Following the transaction, the insider now directly holds 1.48 million shares of the HJLI stock.

Still, SEC filings show that on Aug 19, Biodyne Holding, S.A. (Former 10% Owner) disposed off 50,000 shares at an average price of $0.30 for $15000.0. The insider now directly holds 1,555,433 shares of Hancock Jaffe Laboratories Inc. (HJLI).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

7 GROWTH STOCKS FOR 2021

Download Free eBook For

100% free. stop anytime no spam